Navigation Links
PermaDerm™ Receives National Media Coverage
Date:3/8/2011

LITTLE FALLS, N.J., March 8, 2011 /PRNewswire/ -- PermaDerm™, an engineered skin substitute which is being developed to be the only tissue-engineered skin prepared from a patient's own skin cells, has been attracting national media attention ever since it was announced that the U.S. Department of Defense awarded more than $18 million in funding for the development and commercialization of the therapeutic candidate for the treatment of severe burns among U.S. troops and civilians.  

Since November, PermaDerm has received coverage by the Associated Press, the LA Times, UPI, Bloomberg Business Week, and several other national publications. In addition, ABC News featured a story in their on-line edition on eight-year old, Alfred Real and his return home following a severe burn over 80% of his body. The FDA allowed Real to be treated with the engineered skin substitute this past summer.

Regenicin, Inc. (OTC Bulletin Board: RGIN), through its know-how license and other contractual rights, is working with PermaDerm's manufacturer to obtain FDA approval for the commercial sale of PermaDerm.  The recent funding given to the manufacturer from the D.O.D. will, among other things, assist in advancing the adult clinical trials to be conducted in connection with the FDA approval process.  Regenicin will continue working toward its goal with the manufacturer to achieve interim and final federal regulatory approval.

PermaDerm has already been used to treat more than 150 pediatric, catastrophic burn victims through an Investigation Device Exemption issued by U.S. Food and Drug Administration (FDA). The initial clinical trials will contain 10 patients, both male and female, between the ages of 18 and 40, who suffer full thickness burns over a large area of their body.  These trials and future trials will take place at 2 sites, the United States Army Institute of Surgical Research at Fort Sam Houston and a second site still to be determined.

About Regenicin

Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market.   The company is publicly traded with headquarters in New Jersey.

Safe Harbor Statement.  This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition.  A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission.  The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray ... showcase a healthy CAGR during the forecast period ... in the global digital mobile X-Ray devices market, which is ... in 2017, expanding at a CAGR of 7% over the ... $ opportunity of more than US$ 100 Mn in 2017 ...
(Date:4/19/2017)... , Tenn. and DALLAS , April ... EndoStim, Inc., announced that the first patients in ... the EndoStim device in the Lower Esophageal Sphincter Stimulation ... a minimally-invasive implantable device designed to provide long-term reflux ... neurostimulation. GERD affects nearly 65 million people ...
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured to have ... UK’s most prestigious award for business success. The company has been recognized ... has grown by a total of 400% over the last six years. , ...
(Date:4/21/2017)... ... 21, 2017 , ... Providing for loved ones before one’s passing is of ... to even begin. “Now more than ever there are some questions that are far ... your family,” said attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa ...
(Date:4/21/2017)... ... ... Westside Dental Associates and its owner, Dr. Les Latner, have ... Latner has become one of the Los Angeles area’s premier dentists. “It’s been an ... their dental needs,” said Dr. Latner, who was recently named Chairperson of the ...
(Date:4/21/2017)... ... April 21, 2017 , ... Each year, everyone is urged to give back ... trees and look forward to a better future. However, supporting the environment should be ... air quality can be two to five times more polluted than outdoor air, reports ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal mandate, fines, controversy, ... between the Obamacare program that most Republicans love to hate and Texas Agriculture ... kill hogs. , Like Obamacare, the Miller program centers upon a federal ...
Breaking Medicine News(10 mins):